✦ LIBER ✦

Repaglinide, a Novel, Short-Acting Hypoglycemic Agent for Type 2 Diabetes Mellitus

✍ Scribed by David R. P. Guay

Book ID: 112113760
Publisher: John Wiley and Sons
Year: 1998
Tongue: English
Weight: 857 KB
Volume: 18
Category: Article
ISSN: 0277-0008
DOI: 10.1002/j.1875-9114.1998.tb03137.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of Short-Acting Insulin Secretagogue

Use of Short-Acting Insulin Secretagogues for Type 2 Diabetes Mellitus

✍ Maribel Salas, Dr Jamie Banks 📂 Article 📅 2005 🏛 Adis International Limited (now part of Wolters Kl 🌐 English ⚖ 106 KB

Critical Delay of the Hypoglycemic Effec

Critical Delay of the Hypoglycemic Effect of Short- Acting Insulin Analogues in Obese Subjects with Type 2 Diabetes Mellitus.

✍ Gagnon-Auger, Maude; Baillargeon, Jeanpatrice; Martin, Elizabeth; Menard, Julie; 📂 Article 📅 2008 🏛 Canadian Diabetes Association 🌐 English ⚖ 569 KB

Otelixizumab: a novel agent for the prev

Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus

✍ Miller, Shannon A; St. Onge, Erin 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 322 KB

Vildagliptin: A novel oral therapy for t

Vildagliptin: A novel oral therapy for type 2 diabetes mellitus

✍ Lauster, C. D.; McKaveney, T. P.; Muench, S. V. 📂 Article 📅 2007 🏛 American Society of Health-System Pharmacists 🌐 English ⚖ 317 KB

Inhibition of SGLT2: A Novel Strategy fo

Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus

✍ List, J F; Pfister, M; Whaley, J M; Zhang, L 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 282 KB

Cycloset (Quick-Release Bromocriptine Me

Cycloset (Quick-Release Bromocriptine Mesylate), a Novel Centrally Acting Treatment for Type 2 Diabetes

✍ Cincotta, Anthony H.; Gaziano, J. Michael; Ezrokhi, Michael; Scranton, Richard E 📂 Article 📅 2008 🏛 Canadian Diabetes Association 🌐 English ⚖ 653 KB